Kyverna Shares Rise on Positive Long-Term Trial Results

Dow Jones

Apr 21

By Katherine Hamilton

Kyverna Therapeutics shares rose after the company shared positive longer-term data from a Phase 2 trial of an autoimmune treatment.

The stock gained 13% to $11.27 on Monday. Shares have climbed 19% this year.

The late-stage clinical biopharmaceutical company said updated data from the trial of miv-cel in patients with myasthenia gravis, an autoimmune disorder, showed deep and durable responses across all key clinical outcome measures.

There was also sustained benefit observed out to one year following a single dose of miv-cel, Kyverna said. The treatment was also well tolerated, the company added.

All of the patients treated achieved clinically meaningful, rapid and sustained reductions in trial endpoint scores from the baseline, Kyverna said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 20, 2026 13:44 ET (17:44 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2629720709"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629720709\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629720709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629720709","market":"nz","top_or_hot":-1,"title":"Kyverna Shares Rise on Positive Long-Term Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> shares rose after the company shared positive longer-term data from a Phase 2 trial of an autoimmune treatment. \n</p>\n<p>\n  The stock gained 13% to $11.27 on Monday. Shares have climbed 19% this year. \n</p>\n<p>\n  The late-stage clinical biopharmaceutical company said updated data from the trial of miv-cel in patients with myasthenia gravis, an autoimmune disorder, showed deep and durable responses across all key clinical outcome measures. \n</p>\n<p>\n  There was also sustained benefit observed out to one year following a single dose of miv-cel, Kyverna said. The treatment was also well tolerated, the company added. \n</p>\n<p>\n  All of the patients treated achieved clinically meaningful, rapid and sustained reductions in trial endpoint scores from the baseline, Kyverna said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 20, 2026 13:44 ET (17:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kyverna Shares Rise on Positive Long-Term Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKyverna Shares Rise on Positive Long-Term Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-21 01:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> shares rose after the company shared positive longer-term data from a Phase 2 trial of an autoimmune treatment. \n</p>\n<p>\n  The stock gained 13% to $11.27 on Monday. Shares have climbed 19% this year. \n</p>\n<p>\n  The late-stage clinical biopharmaceutical company said updated data from the trial of miv-cel in patients with myasthenia gravis, an autoimmune disorder, showed deep and durable responses across all key clinical outcome measures. \n</p>\n<p>\n  There was also sustained benefit observed out to one year following a single dose of miv-cel, Kyverna said. The treatment was also well tolerated, the company added. \n</p>\n<p>\n  All of the patients treated achieved clinically meaningful, rapid and sustained reductions in trial endpoint scores from the baseline, Kyverna said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 20, 2026 13:44 ET (17:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYTX","symbol_name":"Kyverna Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629720709","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629720709","pubTimestamp":1776707040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kyverna Therapeutics shares rose after the company shared positive longer-term data from a Phase 2 trial of an autoimmune treatment.The stock gained 13% to $11.27 on Monday. Shares have climbed 19% this year.The late-stage clinical biopharmaceutical company said updated data from the trial of miv-cel in patients with myasthenia gravis, an autoimmune disorder, showed deep and durable responses across all key clinical outcome measures.There was also sustained benefit observed out to one year following a single dose of miv-cel, Kyverna said. The treatment was also well tolerated, the company added.All of the patients treated achieved clinically meaningful, rapid and sustained reductions in trial endpoint scores from the baseline, Kyverna said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYTX":"Kyverna Therapeutics","BK4139":"生物科技"},"translate_title":"Kyverna股价因积极的长期试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYTX":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\nKyverna Therapeutics shares rose after the company shared positive longer-term data from a Phase 2 trial of an autoimmune treatment. \n\n\n  The stock gained 13% to $11.27 on Monday. Shares have climbed 19% this year. \n\n\n  The late-stage clinical biopharmaceutical company said updated data from the trial of miv-cel in patients with myasthenia gravis, an autoimmune disorder, showed deep and durable responses across all key clinical outcome measures. \n\n\n  There was also sustained benefit observed out to one year following a single dose of miv-cel, Kyverna said. The treatment was also well tolerated, the company added. \n\n\n  All of the patients treated achieved clinically meaningful, rapid and sustained reductions in trial endpoint scores from the baseline, Kyverna said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 20, 2026 13:44 ET (17:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}